Why the study?
Does ET(A)-receptor antagonist ABT-627 prevent arterial pressure increases and renal hemodynamic changes in a rat model of chronic ANG II-induced hypertension?
Does ET(A)-receptor antagonist ABT-627 prevent arterial pressure increases and renal hemodynamic changes in a rat model of chronic ANG II-induced hypertension?
Answers are grounded in this paper and cite their sources.
ET(A)-receptor antagonism abolishes the hypertensive effect and attenuates the GFR decrease induced by chronic ANG II infusion in rats, suggesting the renal endothelin system mediates these actions.
The purpose of this study was to determine the role of endothelin in mediating the renal hemodynamic and arterial pressure changes observed during chronic ANG II-induced hypertension. ANG II (50 ng x kg(-1) x min(-1)) was chronically infused into the jugular vein by miniosmotic pump for 2 wk in male Sprague-Dawley rats with and without endothelin type A (ET(A))-receptor antagonist ABT-627 (5 mg x kg(-1) x day(-1)) pretreatment. Arterial pressure increased in ANG II rats compared with control rats (149 +/- 5 vs. 121 +/- 6 mmHg, P < 0.05, respectively). Renal expression of preproendothelin mRNA was increased by approximately 50% in both the medulla and cortex of ANG II rats. The hypertensive effect of ANG II was completely abolished in rats pretreated with the ET(A)-receptor antagonist (114 +/- 5 mmHg, P < 0.05). Glomerular filtration rate was decreased by 33% in ANG II rats, and this response was attenuated in rats pretreated with ET(A)-receptor antagonist. These data indicate that activation of the renal endothelin system by ANG II may play an important role in mediating chronic renal and hypertensive actions of ANG II.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: